The growing interest in targeted radionuclide therapy (TRT) for a broad range of applications is shared by a diverse group of medical professionals, including but not limited to physicians and basic scientists in several fields, as well as members of industry, regulatory bodies, and patients.
No takes yet. Share an insight, caveat, or question.
Fahey et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: